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Abstract
Fine-needle aspiration biopsy (FNA) is usually applied to distinguish benign from malignant thyroid nodules. However,
cytological analysis cannot always allow a proper diagnosis. We believe that the improvement of the diagnostic capability of
pre-surgical FNA could avoid unnecessary thyroidectomy. In a previous study, we performed a proteome analysis to
examine FNA collected after thyroidectomy. With the present study, we examined the applicability of these results on pre-
surgical FNA. We collected pre-surgical FNA from 411 consecutive patients, and to obtain a correct comparison with our
previous results, we processed only benign (n = 114), papillary classical variant (cPTC) (n = 34) and papillary tall cell variant
(TcPTC) (n = 14) FNA. We evaluated levels of five proteins previously found up-regulated in thyroid cancer with respect to
benign nodules. ELISA and western blot (WB) analysis were used to assay levels of L-lactate dehydrogenase B chain (LDHB),
Ferritin heavy chain, Ferritin light chain, Annexin A1 (ANXA1), and Moesin in FNA. ELISA assays and WB analysis confirmed
the increase of LDHB, Moesin, and ANXA1 in pre-surgical FNA of thyroid papillary cancer. Sensitivity and specificity of
ANXA1 were respectively 87 and 94% for cPTC, 85 and 100% for TcPTC. In conclusion, a proteomic analysis of FNA from
patients with thyroid nodules may help to distinguish benign versus malignant thyroid nodules. Moreover, ANXA1 appears
to be an ideal candidate given the high sensitivity and specificity obtained from ROC curve analysis.
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Introduction
Nodular thyroid disease is a frequent finding in clinical practice
and it is diagnosed in 4 to 7% of the adult population [1].
However, the incidence of thyroid cancer is low and most thyroid
nodules are benign. The annual incidence of thyroid cancer in
areas not affected by nuclear fallout has been reported to range
between 1.2 and 2.6 cases per 100,000 in men and between 2.0
and 3.8 cases per 100,000 in women, with higher incidences in
countries, such as Sweden, France, Japan, and the United States
[2,3].
Ultrasound guided fine-needle aspiration (FNA) cytology is a
safe and sensitive diagnostic procedure in the management of
thyroid lesions. The application of proteomics to pre-surgical FNA
could improve the diagnosis of thyroid nodules reducing
unnecessary thyroidectomies with a positive impact on health
care costs and patient treatment. The identification and validation
of a diagnostic proteomic biomarker panel would be very helpful
in distinguishing benign from malignant nodules.
Until now many studies have been carried out in thyroid cancer
research, and over the last years, besides genetic studies,
proteomics has made headway in discovering potential thyroid
biomarkers. Proteins are excellent targets in disease diagnosis and
can be extracted from serum [4], tissues [5–7], and cell cultures
[8,9] for analysis with different techniques.
In a previous study, we performed a comparative proteome
analysis to examine FNA collected immediately after total
thyroidectomy [10]. We investigated the global changes of FNA
protein patterns of two variants of malignant papillary thyroid
cancer (PTC): the classical variant PTC (cPTC) and the tall cell
variant PTC (TcPTC). Differences in protein expression between
tumor and non-tumor tissue were identified using two-dimensional
electrophoresis (2DE) and matrix-assisted laser desorption ioniza-
tion time-of-flight/mass spectrometry (MALDI-TOF/MS) [10].
Our study allowed us to highlight proteins which were useful to
give insights on molecular mechanisms of thyroid tumours and for
this reason, we considered it was worth transferring this
information on the less invasive pre-surgical FNA. Therefore,
with the present study, we aimed to examine the applicability of
results obtained on the surgical specimens on a larger number of
pre-surgical thyroid FNA samples. Hence, we evaluated the levels
of five proteins, previously found up-regulated in cancer with
respect to controls, by enzyme-linked immunosorbent assay
(ELISA) kit and western blot analysis (WB). We decided to test
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proteins with different functional properties, considering both the
fold variation and the p-value in each functional class that we
found in our previous study. These proteins were L-lactate
dehydrogenase B chain (LDHB); Ferritin heavy chain (FHC);




This study adopted a phased approach. In the first part we
collected pre-surgical FNAs from 411 consecutive patients. After
their histological examination, we selected 162 samples from this
large cohort of patients because we processed only benign, cPTC,
and TcPTC FNAs. This choice was made to obtain a correct
comparison with the results described in our previous work for
surgical specimens. In the second phase we performed WB and
ELISA to evaluate in these samples the levels of five proteins that
we found up-regulated in cancer respect to control in our previous
work. Our interest was to examine, on the pre-surgical thyroid
FNAs, the applicability of results obtained on the surgical
specimens. Finally, since ROC curves pointed out the ability of
ANXA1 in separating malignant and benign groups, we investi-
gated the levels of this protein in a subset of FNAs from patients
with follicular lesion of undetermined significance.
Patients
Ultrasound-guided FNA was performed as a part of the
standard diagnostic protocol for patients with thyroid nodules in
the Department of Endocrinology at the University of Pisa in Italy.
Great care was given to collect only material from nodular lesions
with the help of ultrasound. After the aspirate was smeared for
conventional cytology, the leftover material in the needle was
washed with 300 ml of saline solution and the liquid centrifuged at
2300xg for 10 min at 4uC. The supernatants were stored at280uC
until use.
A specimen was considered as satisfactory if there were six
groups of epithelial cells with at least 10 cells per group. According
to FNA analysis, the nodules were classified as benign, follicular
lesions of undetermined significance (FLUS) (high to moderate
cellularity and the presence of microfollicular pattern of growth
with or without Hurthle cell change and scant colloid), suspicious
for malignancy or malignant, and non-diagnostic or inadequate
(due to limited cellularity or poor preservation and fixation),
following the guidelines of National Cancer Institute thyroid fine
needle aspiration state of the science conference [11].
We collected FNA samples from 411 consecutive patients,
without considering clinical or other parameters. Cytological
evaluation classified these FNAs in benign (n = 254), FLUS
(n = 76), malignant (n = 25), suspicious for malignancy (n= 21) or
non diagnostic (n = 35). All the patients with benign thyroid
nodules were followed conservatively for at least 5 years by annual
ultrasound examination. The patients with malignant or suspicious
for malignancy or FLUS underwent thyroid surgery after
completion of the clinical and cytological evaluation. The
histological examination, after surgical intervention, completed
the diagnosis for these samples. To obtain a correct comparison
with the results described in our previous work for surgical
specimens [10], we processed only benign (n= 114), cPTC
(n= 34), and TcPTC (n= 14) FNA samples found in our cohort
of patients. These PTC have had a cytological evaluation as
benign (n= 114), malignant (n = 24), suspicious for malignancy
(n = 20) and FLUS (n= 4). Moreover, we selected 24 FNAs from
patients with FLUS (cPTC n=4, follicular carcinoma n= 17,
trabecular carcinoma n= 3) for the further validation of ANXA1.
Serum thyroxin (FT4), thriiodothyronine (FT3) and thyrotropin
(TSH) values were in the normal range in all patients. No serum
antithyreoglobuline (TgAb) and antithyreoperoxidase (TPOAb)
antibodies were detectable. Serum calcitonin was undetectable in
all patients.
Laboratory evaluation of thyroid function. Serum free
FT4 and free FT3 were measured with a chemiluminescent
method (Vitro System, Ortho-Clinical Diagnostics, Rochester,
NY, USA). TSH was assessed by ultrasensitive commercial
chemiluminescent method (Immulite 2000; Diagnostic Products,
Los Angeles, CA, USA). TPOAb and TgAb were measured using
a two-step immunoenzymatic assay (AIA-Pack TgAb and TPOAb;
Tosoh, Tokyo, Japan). Serum calcitonin was measured by
immunoradiometric assay (CisBio International, Gif-sur-Yvette,
France).
Ethics statements. This study was approved by the Local
Ethics Committee (Comitato per la Sperimentazione Clinica dei
Farmaci, Azienda Ospedaliera Universitaria Pisana; reference
number 3016) and signed consent forms were obtained from all
patients.
ELISA Assay
The levels of LDHB, FHC, FLC and Moesin were detected by
enzyme-linked immunosorbent assay (ELISA) kits (Uscn life science
Inc.) according to the manufacturer’s instructions. The Lower
Limit of Detection of these assays was less than 1.14 ng/ml;
5.5 pg/ml; 14.7 pg/ml l; and 0.059 ng/ml for LDHB, FHC, FLC,
and Moesin respectively.
Western Blotting
WB analysis was performed to estimate ANXA1 levels in FNA.
10 mg of proteins were resolved by 12% SDS-PAGE gels and
transferred onto nitrocellulose membranes (0.2 mm) using a
voltage of 100 V for 30 min (Criterion Blotter, Biorad, CA,
USA). Non-specific binding was prevented by blocking the
membranes with 3% low fat dried milk, 0.2% (v/v) Tween 20 in
PBS (10 mM NaH2PO4, pH 7.4, 0.9% NaCl) (PBS/milk) for 1 h
at room temperature. After their blocking, the membranes were
incubated overnight at 4uC in PBS/milk containing primary
antibody ANXA1 (rabbit monoclonal, 1:1000 dilution; Cell
Signaling Technology, MA, USA). HRP-conjugated goat anti-
rabbit (1:10000 dilution; Stressgen, NY, USA) was used as a
secondary antibody. Immunoblots were developed using the ECL
detection system (PerkinElmer, MA, USA). The chemiluminescent
images were acquired by LAS4010 (GE Health Care, WI, USA).
For the comparison of protein expression levels, the antigen-
specific bands were quantified using the Image Quant-L (GE
Health Care, WI, USA).
Statistical Analysis
Results were expressed as mean 6 SEM. Differences between
groups were determined using Student’s t test. Data were
considered statistically significant at p-value ,0.05. Receiver
operating characteristic (ROC) curve was performed to assess
sensitivity and specificity (MedCalc 9.6.4.0 software).
Results
Validation of Differentially Expressed Proteins by ELISA
and WB Analysis
In order to verify the analogy of pre- and post- surgical thyroid
FNA samples we compared their proteome profile (Figure 1 A and
Thyroid Cancer Biomarkers
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B). Pre-surgical FNA samples were pooled according to their
different classes (benign, cPTC, TcPTC) and subjected to 2DE (see
Methods S1). Gel images were analysed with the Progenesis Same
Spot v4.1 (Nonlinear Dynamics) software [12]. This software
includes the SpotCheck function. SpotCheck is a separate quality
control (QC) workflow within Progenesis Same Spot v4.1 which
allowed us to assess objectively the quality of our gels images. For
each class of gels (benign, cPTC, and TcPTC) we selected a gold
standard one (a reference gel) and each gel was tested against it.
Therefore we compared pre- against post-surgical FNA and we
obtained coefficients of variation (CV) ranging from 91.9 to 85%
confirming a strong analogy between pre- and post-surgical FNA
samples. Moreover, by using the software, we were able to locate
our five protein spots in the gel image of pre-surgical FNA. These
spots were cut out from the gel and identified by NanoLC-ESI-
MS/MS analysis (see Methods S1). Thus, we confirmed the
identification of our five selected proteins.
Then, using ELISA assay or WB analysis, the different
expression of five proteins of interest was validated. Figure 2,
panel A shows the results previously obtained by 2DE analysis for
LDHB and moesin in post-surgical FNA. Panel B shows the
ELISA array detection results for LDHB and moesin in pre-
surgical FNA. With ELISA assay we confirmed the significant
increase of LDHB found with 2DE in both two variants of
malignant PTC respect to benign controls (B), (p = 0.0078 B vs
cPTC, and p= 0.0012 B vs TcPTC) (table 1). Moesin resulted up-
regulated only in cPTC after 2DE analysis, but the validation with
ELISA in a larger number of samples highlighted also an increase
in TcPTC compared to controls (table 1). With regard to ferritins,
the significant increase of expression for FHC (p= 0.011) and FLC
(p= 0.015) was confirmed in pre-surgical FNA of cPTC variant,
but not in TcPTC.
Finally, to obtain a specific validation of ANXA1 in pre-surgical
FNA samples and to eliminate potential cross-reactions in ELISA
kit due to the high homology of members of annexin family, we
carried out WB analysis using an antibody directed against a
synthetic peptide corresponding to residues surrounding Val236 of
human ANXA1 protein. WB pointed out the significant up-
regulation of ANXA1 in cPTC and TcPTC, showing almost the
absence of this protein in controls (Figure 3).
ROC Curves
ROC curves were calculated to evaluate the ability of selected
proteins to separate malignant and benign groups. For LDHB
sensitivity and specificity were respectively 78 and 59% for cPTC,
and 46 and 94% for TcPTC. Moesin showed a sensitivity of 64
and 79% and a specificity of 80 and 54% for cPTC and TcPTC
respectively. Sensitivity was 95 and 55%, and specificity 47 and
82% for FHC and FLC, respectively, in cPTC, while in TcPTC
the significant increase of ferritins was not confirmed.
Finally, ANXA1 showed better results compared to the above
mentioned proteins (Figure 4). The sensitivity and the specificity of
the ANXA1 were respectively, 87 and 94.3% for cPTC and 84.6
and 100% for TcPTC with a criterion value of 1,09e+05 (cPTC)
and 5,07e+05(TcPTC). The negative predictive value (NPV) was
0.92 and 0.95 for cPTC and TcPTC respectively, whereas the
positive predictive value (PPV) was 0.91 and 1 for cPTC and
TcPTC respectively (Figure 4).
Expression of ANXA1 in FNAs Suspicious for Follicular
Neoplasm and Suspicious for Malignancy
The levels of ANXA1 were evaluated by WB analysis in a subset
of FNAs suspicious for follicular neoplasm and suspicious for
malignancy. As depicted in figure 5, samples were separated
according to cytological and histological examination. Our results
pointed out the significant up-regulation of ANXA1 in all type of
cancer respect to control.
Discussion
In our previous work we studied PTC samples using 2DE and
MALDI-TOF/MS. The research was carried out on 13 samples of
FNA collected after total thyroidectomy and in which we found
changes in protein expression between cPTC, TcPTC, and
controls. Our results demonstrated that FNA may be used in the
comparative analysis of thyroid tumours [10]. In the present work
we tested the possibility to transfer these findings also on pre-
surgical FNA, since it is usually applied for the detection of thyroid
cancer. With this purpose, first we compared 2DE patterns of pre-
surgical and post-surgical samples. Then, in a larger number of
pre-surgical FNA samples, we investigated the expression of some
Figure 1. 2DE patterns of human thyroid FNA. Post-surgical TcPTC (A) and pre-surgical (B) TcPTC FNA. A total of 250 mg of proteins was
separated by 2DE using 18 cm pH 3–10NL strips and 12.5% SDS-PAGE (see Methods S1). The five proteins whose levels were evaluated by ELISA kit
and WB are indicated. 1 moesin, 2 ANXA1, 3 LDHB, 4 FHC and 5 FLC.
doi:10.1371/journal.pone.0072911.g001
Thyroid Cancer Biomarkers
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proteins which had been found significantly up-regulated in PTC
in the previous proteomic study. We chose five proteins with
different functional properties: LDHB (metabolism), FHC and
FLC (storage), ANXA1 (apoptosis) and moesin (structural). We
examined ANXA1 expression by WB while ELISA assay was used
for LDHB, FHC, FLC and moesin.
Overall, our results demonstrated the similarity of proteomic
profile of pre-surgical FNA and FNA made on surgical specimens;
moreover, the previous potential biomarkers were confirmed,
suggesting their applicability on the diagnosis of thyroid cancer. In
particular, the alteration of LDHB enzyme expression is widely
documented [13–16]. In fact, it is widely accepted that cancer cells
proliferation is characterized by fermentation of glucose to lactate
[17]. This is the Warburg effect, which is considered as one of the
key features of tumorigenesis and which promotes rapid uncon-
trolled proliferation, but also confers invasive property [18,19]. We
found in PTC a significant up-regulation of LDHB, and in both
studies this increase was greater in cPTC than in TcPTC (Fig. 2 A
and B). The same result was obtained with a structural protein:
moesin. Moesin belongs to the ERM (ezrin, radixin and moesin)
family that takes part in many signalling pathways playing a
crucial role in cell morphology, adhesion and motility [20–22].
Moreover, they have been shown to be involved in carcinogenesis
[23–26]. It has been recently proposed that moesin contributes to
cancer cell proliferation, migration, and invasion in cancer [27]. In
addition to our previous study [10], other authors found moesin
between the differentially expressed proteins in thyroid tumours
Table 1. Results of percentage volume, signal intensity and optical density of proteins studied.
2DE ELISA
%vol (M6SEM) p-value signal intensity (M6SEM) p-value
B cPTC TcPTC BvscPTC BvsTcPTC B cPTC TcPTC BvscPTC BvsTcPTC
LDHB 0.1960.02 0.4960.13 0.4160.1 0.0041 0.0167 3468.7 2606138 188685 0.0078 0.0012
Moesin 0.0260.02 0.1160.02 0.0560.03 0.0175 0.1636 5.860.32 8.960.79 8.361.18 ,0.001 0.006
FLC 0.00560.003 0.1660.05 3.5861.02 ,0.001 ,0.001 2791169447 58801616328 73796840 0.015 0.8
FHC n.d. n.d. 2.6961.2 n.d. ,0.001 7656100 13886286 7606102 0.011 0.9
WB
optical density (M6SEM)
ANXA1 0.0660.02 0.8460.16 0.3760.15 ,0.001 0.0061 3.2e+0461.7e+04 6.2e+0661.7e+06 4.2e+0661.4e+06 ,0.001 ,0.001
n.d. = not detectable.
doi:10.1371/journal.pone.0072911.t001
Figure 2. Expression of LDHB and Moesin in post-surgical and pre-surgical FNA. (A) Histograms of the percentage volumes previously
obtained in FNA of surgical specimens with 2DE for LDHB and Moesin; (B) The ELISA array detection results for LDHB and Moesin in pre-surgical FNA.
Each bar represents the mean 6 SEM of percentage volume and signal intensity. Analysis B vs cPTC, B vs TcPTC (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0072911.g002
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[28,29], and our ELISA assay confirmed the significant up-
regulation of this protein not only in cPTC, but also in TcPTC.
The results obtained with WB of ANXA1 are still in agreement
with those we obtained by 2DE, and they add to many data in
literature that support a possible role of annexin family in the
oncogenic process. In fact, annexins are the most common
proteins in cancers revealed by proteomic and protein functional
studies [30]. As calcium- and phospholipid-binding proteins,
annexins are associated with the lymph node metastasis of
hepatocarcinoma, lung cancer, colon cancer, head and neck
cancer, nasopharyngeal cancer, and oesophageal and oesophago-
gastric junction adenocarcinoma [30]. With regard to thyroid
carcinoma, previous proteomic studies revealed increased levels of
annexin A2, A5, A1 [6,31–33]. In our case in post- and pre-
surgical FNA we also found the up-regulation of ANXA1 [10], a
39 kDa protein that may promote apoptosis [34]. Moreover, it has
been recently proposed that ANXA1 enhances breast cancer
invasion, at least in part, through the activation of NF-kappaB and
the expression of the matrix metalloproteinase -9 gene [35].
Besides this validation of previous results in PTC, we performed
a further evaluation of the levels of ANXA1 in a subset of pre-
surgical FNAs suspicious for follicular neoplasm and suspicious for
malignancy that had a diagnosis of cancer after histological
examination. We found a significant up-regulation of this protein
for each type of cancer, supporting the relevance of ANXA1 as
ideal candidate biomarker in the diagnosis of thyroid cancer.
Finally, the validation with ELISA assay confirms our previous
findings on ferritins but only in cPTC respect to controls, and not
in TcPTC variants. Therefore, ferritins have not been validated as
a malignant tumour marker in pre-surgical TcPTC FNA. Ferritin
is a protein involved in iron storage, consisting of 24 H (heavy) and
L (light) subunits, encoded by distinct genes [36]. Abnormal
ferritin expression has been observed in a large number of tumour
types, and it has been suggested that it may act as a tumour marker
in neuroblastoma and other cancers, such as hepatic cancer, lung
cancer, leukemia in remission, and breast cancer recurrence or
metastasis [37,38]. Thus, not only is ferritin considered an iron
storage indicator, but also a malignant tumour marker, even if
recently Kim et al. have found that ferritin is not associated with
the risk of cancer [39]. In our previous study we found an
increment of FHC and FLC in TcPTC which has not been
confirmed. Even Deshpande and co-workers did not observe a
significant difference in serum ferritin concentration in thyroid
carcinoma patients as compared to controls, but it appeared to be
Figure 3. Expression of ANXA1 in post-surgical and pre-surgical FNA. (A) Histograms of the percentage volumes previously obtained in FNA
of surgical specimens with 2DE for ANXA1; (B) Western blot analysis of ANXA1 in pre-surgical FNA. Each bar represents the mean 6 SEM of
percentage volume and optical density. Analysis B vs cPTC, B vs TcPTC (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0072911.g003
Figure 4. ROC curve of ANXA1. (A) B vs cPTC; (B) B vs TcPTC. AUC, area under the curve.
doi:10.1371/journal.pone.0072911.g004
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influenced by the presence of metastasis and the type of histology
[40].
In conclusion, having found in the FNA in vivo, and in a larger
number of patients, significant differences in expression of proteins
previously identified in the post-surgical FNA has confirmed the
relevance of these putative biomarkers. Moreover, taken together,
our studies indicate that thyroid FNA is feasible as a potential
source of diagnostic biomarkers for thyroid cancer, and therefore,
there is a clear need to carry out further investigations on other
proteins previously found with 2DE analysis. The goal will be to
identify combined biomarkers that could have potential for clinical
use. In particular, the results obtained with ANXA1 in FLUS are
encouraging for our future research, which is directed at studying
follicular lesions, since their correct surgical management is really
controversial.
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